I initiated a position in GSK recently. The stock is attractively priced, partly due to currency effects, and the weak pound will continue to be a tailwind for the business. The company returned to growth, but it needs to gain more momentum. …
Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing …
Recently, GSK stock has done better, largely on the back of its HIV drug business, which the company had considered spinning off in an initial public offering before deciding to retain it. GSK said its board would consider both internal and …
Dear Mr. Berko: My broker has recommended that I invest $20,000 and buy 500 shares of GlaxoSmithKline, a world-class drug company. The dividend is $2.48 and that yields a very attractive 5.9 percent He thinks Glaxo's problems are …
But the biggest dividend among Big Pharma stocks belongs to GlaxoSmithKline PLC (NYSE:GSK). The Brentford, England-based company’s 5% dividend yield stands well above other health care giants such asJohnson & Johnson …
GSK's stock was trading 0.61% lower at 10.37am in London while Aspen's stock was down 2.96% at 12.21pm in Johannesburg. Shares in GSK have gained some 11.8% so far this year while Aspen's stock has shed some 3%. GSK, …
Federal prosecutors alleged Wednesday that corrupt officials in the Chinese government financially supported and may have benefited from a scheme to steal trade secrets worth billions from a GlaxoSmithKline ... "under the table" stock
Apple lost 1.67% of its value on Friday after a surprising drop in the early afternoon which plunged the stock down over 2% at one point. The stock dropped sharply at about 1:30 PM ET before making a slight comeback. Apparently, a German …
Nomura maintains a reduce rating on GSK Pharma and has also slashed its 12-month target ... However, the market expects strong revival in EBITDA margins and the stock is factoring in possible delisting if parent Glaxo Plc buys back …